Sales Ended

CTAC Patient Group Input Consultation: dolutegravir / rilpivirine

Event Information

Share this event

Date and Time

Event description


CTAC is calling for people living with HIV to take part in a patient consultation so that they can have their voices heard by drug regulators.

Patient input is a cornerstone of CTAC’s work and ensures that the voices of people living with HIV and hepatitis C are heard by the Canadian Drug Expert Committee (CDEC), which makes recommendations to public drug plans about their drug formulary listings as part of the Canadian Agency for Drugs and Technologies In Health (CADTH) Common Drug Review (CDR) process.

This informative webinar, led by CTAC Policy Researcher Amanda Fletcher, will discuss the new two-drug regimen Dolutegravir / rilpivirine and its clinical trials. This webinar is open to all people living with HIV.

Participants will be able to give their views which will be sent the Canadian Drug Expert Committee. The first 20 attendees who complete a survey at the end of the session will be provided with a $10 gift voucher.

Participants will need to log on to to take part. Audio for this webinar will play on your computer.

Find out more at

Date and Time

Save This Event

Event Saved